Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

(MedPage Today) — WASHINGTON — Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), according to new analyses from…